Gilead terminated Phase 1 study of ‘1219, says RBC Capital

RBC Capital reports that newly updated clinicaltrials.gov records show that Gilead’s (GILD) Phase 1 study testing ‘1219, a next-generation longer-acting injectable integrase inhibitors, has been terminated after only four of the expected 30 patients were enrolled. The termination, which follows other setbacks for the HIV life cycle program of late, illustrates HIV life cycle challenges, says the analyst. However, with the Yeztugo launch in near-term focus and recent Biktarvy exclusivity extension providing “more cushion for development of next-gens,” RBC acknowledges a near-term impact on shares may be limited and it maintains a Sector Perform rating on Gilead shares.